Abstract Search

ea0081p34 | Calcium and Bone | ECE2022

Skeletal consequences of long-term replacement therapy with human recombinant PTH(1-34) in chronic hypoparathyroidism

Fischler Rebecca , Lecoq Anne-Lise , Briot Karine , Trabado Severine , Besson Florent , Bouziotis Jason , Goujard Cecile , Salenave Sylvie , Leboulleux Sophie , Carreira Emma , Chabrolle Christine , Bernard Corvilain , Chanson Philippe , Linglart Agnes , Grimon Gilles , Kamenicky Peter

Context: In patients with hypoparathyroidism refractory to conventional treatment, recombinant human (rh)PTH(1-84) or rhPTH(1-34) can be used as second-line therapy and effectively control hypocalcaemia. However, whether rhPTH replacement therapy is safe in the long term is unclear. Our objective was to assess bone effects of long-term therapy of chronic hypoparathyroidism with rhPTH(1-34). Methods: We conducted a monocenter retrospective cross-sectional...

0 shares

Endocrine Abstracts

Skeletal consequences of long-term replacement therapy with human recombinant PTH(1-34) in chronic hypoparathyroidism

BiosciAbstracts